Abstract
Tumor necrosis factor-related apoptosis-inducing ligand is a type II membrane-bound protein whose C-terminal extracellular domain shows clear homology to other tumor necrosis factor family members. It is constitutively expressed on macrophages, T cells, natural killer cells, and dendritic cells and selectively kills transformed cells leaving most of the normal cells alone. This selectivity has led to great interest in it use as a therapeutic agent for the treatment of malignancy. In this review, this critical pathway is described, highlighting its mechanistic manipulation for therapeutic benefit and the recent phase I and II trials in lung cancer that have been performed or are currently ongoing are also discussed.
Original language | English |
---|---|
Pages (from-to) | 983-987 |
Number of pages | 5 |
Journal | Journal of Thoracic Oncology |
Volume | 6 |
Issue number | 6 |
DOIs | |
Publication status | Published - 1 Jun 2011 |
Keywords
- Small cell lung cancer
- Non-small cell lung cancer
- Apoptosis
- TNF-related apoptosis-inducing ligand (TRAIL)
- Clinical trials